(James Cox, a professor of corporate and securities law at Duke University, thought the judge`s decision was unlikely to delay the NYSE`s schedule for pushing through the deal, which is subject to regulatory approval and a seatholder vote.) Strategically I think it is to their advantage to get a strong vote from the membership going forward. I think that strengthens the NYSE`s hand in the litigation arena, ... It`s not uncommon to do the deal and litigate on the sidelines.
- James CoxIf the judgment is that there`s blood on Merck`s (nyse: MRK - news - people ) hands, ... there`s blood on the FDA`s hands as well.
- David GrahamThe NYSE has traditionally been slow to act and slow to investigate.
- Barbara Kaiser